Hui R, Özgüroğlu M, Daniel D, et al. Patient-Reported Outcomes with Durvalumab after Chemoradiation in Locally Advanced, Unresectable NSCLC: Data from PACIFIC. 18th World Conference on Lung Cancer (WCLC) 2017, abstract PL 02.02.
Pembrolizumab plus chemo als eerstelijnsbehandeling bij gevorderde slokdarmkanker
sep 2021 | Immuuntherapie, Maag-darm-leveroncologie